close_btn.png
Healthcare Professionals|Patients/Caregivers rgt_arr.png
Close

You are about to leave NETrospectives and enter a website operated by an independent third party. Please click continue if you wish to be taken to this website.

Cancel
Continue

References

Albert D, Block AM, Bruce BB, eds. Dorland's Illustrated Medical Dictionary. 32nd ed. Philadelphia, PA: Elsevier Saunders; 2012: 1366.

Alexiev BA, Drachenberg CB, Papadimitriou JC. Endocrine tumors of the gastrointestinal tract and pancreas: grading, tumor size and proliferation index do not predict malignant behavior. Diagn Pathol. 2007;28(2):1-8.

Anderson MA, Carpenter S, Thompson NW, Nostrant TT, Elta GH, Scheiman JM. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol. 2000;95:2271-2277.

Ardill JES. Circulating markers for endocrine tumours of the gastrointestinal tract. Ann Clin Biochem. 2008;45:539-559.

Bajetta E, Ferrari L, Martinetti A, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer. 1999;86:858-865.

Banfield A, Green S, Ramage JK. Neuroendocrine tumour management: a team approach. Hosp Med. 2005;66(1):37-42.

Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumours. Endocrine-Related Cancer. 2004;11:1-18.

Bhattacharyya S, Davar J, Dreyfus G, Caplin ME. Carcinoid heart disease. Circulation. 2007;116(24):2860-2865.

Bilimoria KY, Tomlinson JS, Merkow RP, et al. Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients. J Gastrointest Surg. 2007;11:1460-1469.

Chambers AJ, Pasieka JL, Dixon E, Rorstad O. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors. Surgery. 2008;144:645-653.

Chatzipantelis P, Salla C, Konstantinou P, Karoumpalis I, Sakellariou S, Doumani I. Endoscopic ultrasound-guided fine-needle aspiration cytology of pancreatic neuroendocrine tumors. Cancer Cytopathol. 2008:114;255-262.

Choti MA, Bobiak S, Strosberg JR, et al. Prevalence of functional tumors in neuroendocrine carcinoma: an analysis from the NCCN NET database. J Clin Oncol. 2012;(suppl). Abstract 4126.

Creutzfeldt W. Carcinoid tumors: development of our knowledge. World J Surg. 1996:20;126-131.

Dromain C, de Baere T, Lumbruso J, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol. 2005;23(1):70-78.

Ehehalt F, Saeger HD, Schmidt CM, Grützmann R. Neuroendocrine tumors of the pancreas. Oncologist. 2009;14:456-467.

Ezziddin S, Logvinski T, Yong-Hing C, et al. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2006;47:223-233.

Ferolla P, Faggiano A, Mansueto G, et al. The biological characterization of neuroendocrine tumors: the role of neuroendocrine markers. J Endocrinol Invest. 2008;31:277-286.

Ferolla P, Filosso P, Tomassetti P, et al. Thymic neuroendocrine carcinoma (carcinoid) in multiple endocrine neoplasia type 1 syndrome: the Italian series. J Clin Endocrinol Metab. 2005;90:2603-2609.

Fesinmeyer MD, Austin MA, Li CI. Differences in survival by istologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1766-1773.

Formica V, Wotherspoon A, Cunningham D, et al. The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract. Br J Cancer. 2007;96:1178-1182.

Ghosh PK, O'Dorisio TM. Gastrointestinal hormones and carcinoid syndrome. In: Felig P, Frohman L. eds. Endocrinology & Metabolism. 4th ed. McGraw-HUI; 1995:1317-1347.

Gibril F, Jensen RT. Comparative analysis of diagnostic techniques for localization of gastrointestinal neuroendocrine tumors. Yale J Biol Med. 1997;70:509-522.

Goldin SB, Aston J, Wahi MM. Sporadically occurring functional pancreatic endocrine tumors: review of recent literature. Curr Opin Oncol. 2008;20:25-33.

Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19(10):1-7.

Iobenguane sulfate I 131 injection diagnostic [prescribing information]. CIS-US, Inc. Bedford, MA. July 1999.

Janson ET, Holmberg L, Stridsberg M, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol. 1997;8:685-690.

Jensen RT, Berna MJ, Bingham DB, Norton JA. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer. 2008;113(7 suppl):1807-1843.

Jensen RT, Doherty GM. Carcinoid tumors and the carcinoid syndrome. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:1559-1574.

Jensen RT. Endocrine neoplasms of the pancreas. In: Yamada T, Alpers DH, Kalloo AN, Kaplowitz N, Owyang C, Powell DW, eds. Textbook of Gastroenterology. 5th ed. West Sussex, UK: Wiley-Blackwell; 2009:1875-1920.

Jensen RT. Gastrinoma: advances in diagnosis and management. Neuroendocrinology. 2004;80(suppl 1):23-27.

Jensen RT, Niederle B, Mitry, et al. Gastrinoma (duodenal and pancreatic). Neuroendocrinology. 2006;84:173-182.

Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocrine Rev. 2004;25(3):458-511.

Klimstra DS, Modlin IR, Adsay NV, et al. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol. 2010;34(3):300-313.

Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39(6):707-712.

Korse CM, Bonfrer JMG, Aaronson NK, Hart AAM, Taal BG. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine tumors. Neuroendocrinology. 2009;89:296-301.

Krug LM, Kris MG, Rosenzweig K, Travis WD. Small cell and other neuroendocrine tumors of the lung. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. 8th ed. New York, NY: Lippincott Williams & Wilkins; 2008:946-971.

Kulke MH, Anthony LB, Bushnell DL, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010;39:735-752.

Kulke MH. Clinical presentation and management of carcinoid tumors. Hematol Oncol Clin N Am. 2007;21:433-455.

Kulke MH, Siu LL, Tepper JE, et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials planning meeting. J Clin Oncol. 2001;29(7):934-943.

Kumbasar B, Kamel IR, Tekes A, Eng J, Fishman EK, Wahl RL. Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS. Abdom Imaging. 2004;29:696-702.

Lamberts SWJ, Hofland LJ, Nobels FRE. Neuroendocrine tumor markers. Frontiers Neuroendocrinol. 2001;22:309-339.

Le H, Ziogas A, Rhee JM, Lee JG, Lipkin SM, Zell JA. A population-based descriptive analysis of malignant intraductal papillary mucinous neoplasms of the pancreas. Cancer Epidemiol Biomarkers Prev. 2008;17(10):2737-2741.

Lloyd RV. Practical markers used in the diagnosis of neuroendocrine tumors. Endocrine Pathol. 2003;14(4):293-302.

McCormick D. Carcinoid tumors and syndrome. Gastroenterol Nurs. 2002;25(3):105-111.

McStay MKG, Caplin ME. Carcinoid tumour. Minerva Med. 2002;93(5):389-401.

MedLine Plus Medical Encyclopedia. MIBG scintiscan. https://www.nlm.nih.gov/medlineplus/ency/article/003830.htm. Accessed November 23, 2015.

Medscape. Incesu L. Appendicitis imaging. http://emedicine.medscape.com/article/363818-overview. Accessed November 23, 2015.

Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008;135:1469-1492.

Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128:1717-1751.

Modlin IM, Latich I, Zikusoka M, et al. Gastrointestinal carcinoids: the evolution of diagnostic strategies. J Clin Gastroenterol. 2006;40:572-582.

Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934-959.

Modlin IM, Moss SF, Chung DC, Jensen RT, Snyderwine E. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst. 2008;100(18):1282-1289.

Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9(1):61-72.

Møller JE, Connolly HM, Rubin J, Seward JB, Modesto K, Pellikka PA. Factors associated with progression of carcinoid heart disease. N Engl J Med. 2003;348:1005-1015.

Mullen JT, Wang H, Yao JC, et al. Carcinoid tumors of the duodenum. Surgery. 2005;138:971-978.

NANETS: Current clinical trials. http://www.nanets.net/research. Accessed October 17, 2012.

National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Cancer Statistics Review, 1975-2004. http://seer.cancer.gov/csr/1975_2004/. Accessed December 20, 2012.

National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology: Neuroendocrine Tumors. V.1.2015.

Öberg K, Astrup L, Eriksson B, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Acta Oncologica. 2004;43(7):617-625.

Öberg K. Biochemical diagnosis of neuroendocrine GEP tumor. Yale J Biol Med. 1997;70:501-508.

Oberg K. Neuroendocrine tumors: recent progress in diagnosis and treatment. Endocrine Relat Cancer. 2011;18:E3-E6.

Oberg K, Stridsberg M. Chromogranins as diagnostic and prognostic markers in neuroendocrine tumours. In: Helle KB, Aunis D, eds. Chromogranins: Functional and Clinical Aspects. New York, NY: Kluwer Academic/Plenum Publishers; 2000:329-337.

Ong SL, Garcea G, Pollard CA, et al. A fuller understanding of pancreatic neuroendocrine tumours combined with aggressive management improves outcome. Pancreatology. 2009;9:583-600.

Paulson EK, McDermott VG, Keogan MT, DeLong DM, Frederick MG, Nelson RC. Carcinoid metastases to the liver: role of triple-phase helical CT. Radiology. 1998;206:143-150.

Peracchi M, Conte D, Gebbia C, et al. Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1. Eur J Endocrinol. 2003;148:39-43.

Phan AT, Öberg K, Choi J, et al. NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas. 2010;39:784-798.

Rajekar H, Bogammana K, Stubbs RS. Selective internal radiation therapy for gastrointestinal neuroendocrine tumour liver metastases: a new and effective modality for treatment. Intl J Hepatol. 2011; epub Nov 15:1-7.

Ramage JK, Davies AHG, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005;54(suppl 4):iv1-iv16.

Reznek RH. CT/MRI of neuroendocrine tumours. Cancer Imaging. 2006;6:S163-S177.

Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman F, Carneiro F, Hruban R, Theise N, eds. WHO Classification of Tumours of the Digestive System Lyon, France: IARC Press, 2010.

Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol. 2005;89:151-160.

Scharfmann R, Xiao X, heimberg H, Mallet J, Ravassard P. Beta cells within single human islets originate from multiple progenitors. PLoS ONE. 2008;3(10):1-8.

Shi W, Johnston CF, Buchanan KD, et al. Localization of neuroendocrine tumours with [111In]DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging. Q J Med. 1998;91:295-301.

Sobol RE, Memoli V, Deftos LI. Hormone-negative, chromogranin A-positive endocrine tumors. N Engl J Med. 1989: 320(7):444-447.

Steinmüller T, Kianmanesh R, Falconi M, et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2008;87:47-62.

Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology. 2009;89:471-476.

Strosberg JR, Nasir A, Hodul P, Kvols L. Biology and treatment of metastatic gastrointestinal neuroendocrine tumors. Gastrointest Cancer Res. 2008;2:113-125.

Toth-Fejel S, Pommier RF. Relationships among delay of diagnosis, extent of disease, and survival in patients with abdominal carcinoid tumors. Am J Surg. 2004;187(5):575-579.

Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243-1260.

Vaidakis D, Karoubalis J, Pappa T, Piaditis G, Zografos GN. Pancreatic insulinoma: current issues and trends. Hepatobiliary Pancreat Dis Int. 2010;9(3):234-241.

Vinik AI, Silva MP, Woltering G, Go VLW, Warner R, Caplin M. Biochemical testing for neuroendocrine tumors. Pancreas. 2009;38:876-889.

Vinik AI, Woltering EA, O'Dorisio TM, Go VLW, Mamikunian G. Diagnosing and treating gastroenteropancreatic tumors, including ICD-9 codes. In: Neuroendocrine Tumors: A Comprehensive Guide to Diagnosis and Management. 5th ed. Inglewood, CA: Inter Science Institute; 2012:1-56.

Vortmeyer AO, Huang S, Lubensky I, Zhuang Z. Non-islet origin of pancreatic islet cell tumors. J Clin Endocrinol Metab. 2004;89:1934-1938.

Welin S, Maleka A, Oberg K, Eriksson B, Janson ET. Survival and clinical characteristics in 284 patients with midgut carcinoid tumors. Eur J Clin Invest. 2009;39(Suppl 1):17-45. Abstract 207.

Yao JC, Eisner MP, Leary C, et al. Population-based study of islet cell carcinoma. Ann Surg Oncol. 2007;14(12):3492-3500.

Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063-3072.

Yao J, Rindi G, B D. Pancreatic endocrine tumors. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. 8th ed. New York, NY: Lippincott Williams & Wilkins; 2008:1702-1721.

Zell J, Rhee J, Ziogas A, et al. Race, Socioeconomic Status, Treatment, and Survival Time among Pancreatic Cancer Cases in California. Cancer Epidem Biomark Prev. 2007;16(3):546-552.

Zuetenhorst JM, Taal BG. Metastatic carcinoid tumors: a clinical review. Oncologist. 2005;10:123-131.